• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Compartmental pharmacokinetics and tissue drug distribution of the pradimicin derivative BMS 181184 in rabbits.普拉地米星衍生物BMS 181184在兔体内的房室药代动力学和组织药物分布
Antimicrob Agents Chemother. 1998 Oct;42(10):2700-5. doi: 10.1128/AAC.42.10.2700.
2
Compartmental pharmacokinetics and tissue distribution of multilamellar liposomal nystatin in rabbits.多室脂质体制霉菌素在兔体内的房室药代动力学及组织分布
Antimicrob Agents Chemother. 2000 Apr;44(4):950-7. doi: 10.1128/AAC.44.4.950-957.2000.
3
Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits.抗真菌棘白菌素脂肽米卡芬净(FK463)在兔体内的房室药代动力学及组织分布
Antimicrob Agents Chemother. 2001 Dec;45(12):3322-7. doi: 10.1128/AAC.45.12.3322-3327.2001.
4
Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits.静脉注射抗真菌三唑类药物雷夫康唑的二赖氨酸磷酸酯前药(BMS-379224)后,其在兔体内的房室药代动力学和组织分布情况。
J Antimicrob Chemother. 2005 Nov;56(5):899-907. doi: 10.1093/jac/dki287. Epub 2005 Sep 19.
5
Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.阿尼芬净(LY303366)的药代动力学和药效学建模:利用最佳血浆采样对其在机会性真菌病中性粒细胞减少动物模型中的疗效进行重新评估。
Antimicrob Agents Chemother. 2001 Oct;45(10):2845-55. doi: 10.1128/AAC.45.10.2845-2855.2001.
6
Antifungal activity of the pradimicin derivative BMS 181184 in the treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.普拉地米星衍生物BMS 181184在治疗持续性中性粒细胞减少兔实验性肺曲霉病中的抗真菌活性。
Antimicrob Agents Chemother. 1998 Sep;42(9):2399-404. doi: 10.1128/AAC.42.9.2399.
7
Comparative drug disposition, urinary pharmacokinetics, and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbits.多层脂质体制霉菌素和两性霉素B脱氧胆酸盐在兔体内的药物处置比较、尿药代动力学及对肾脏的影响
Antimicrob Agents Chemother. 2003 Dec;47(12):3917-25. doi: 10.1128/AAC.47.12.3917-3925.2003.
8
Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits.抗真菌棘白菌素类药物卡泊芬净(MK-0991)在兔体内的房室药代动力学。
Antimicrob Agents Chemother. 2001 Feb;45(2):596-600. doi: 10.1128/AAC.45.2.596-600.2001.
9
Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts.Bcl-2反义寡核苷酸(G3139)联合阿霉素在携带人乳腺癌实体瘤异种移植瘤的SCID小鼠体内的药代动力学
Cancer Chemother Pharmacol. 2002 Jan;49(1):57-68. doi: 10.1007/s00280-001-0385-3.
10
Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats.17-(二甲基氨基乙基氨基)-17-去甲氧基格尔德霉素(NSC 707545)在CD2F1小鼠和Fischer 344大鼠体内的药代动力学、组织分布及代谢
Cancer Chemother Pharmacol. 2002 Jan;49(1):7-19. doi: 10.1007/s00280-001-0380-8.

引用本文的文献

1
Carbohydrate-Binding Non-Peptidic Pradimicins for the Treatment of Acute Sleeping Sickness in Murine Models.用于治疗小鼠模型急性昏睡病的碳水化合物结合非肽类制霉菌素
PLoS Pathog. 2016 Sep 23;12(9):e1005851. doi: 10.1371/journal.ppat.1005851. eCollection 2016 Sep.
2
Synergistic actions of tailoring enzymes in pradimicin biosynthesis.纳他霉素生物合成中定制酶的协同作用。
Chembiochem. 2014 Oct 13;15(15):2289-96. doi: 10.1002/cbic.201402306. Epub 2014 Aug 22.
3
Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus.普拉地米星A,一种用于治疗由具有高度糖基化包膜的病毒引起的感染的碳水化合物结合非肽类先导化合物,如人类免疫缺陷病毒。
J Virol. 2007 Jan;81(1):362-73. doi: 10.1128/JVI.01404-06. Epub 2006 Oct 18.

本文引用的文献

1
Trends in the postmortem epidemiology of invasive fungal infections at a university hospital.某大学医院侵袭性真菌感染的尸检流行病学趋势
J Infect. 1996 Jul;33(1):23-32. doi: 10.1016/s0163-4453(96)92700-0.
2
Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients.中性粒细胞减少患者侵袭性真菌感染治疗的最新进展与当前问题
Infect Dis Clin North Am. 1996 Jun;10(2):365-400. doi: 10.1016/s0891-5520(05)70303-2.
3
The future of antifungal therapy.
Clin Infect Dis. 1996 May;22 Suppl 2:S166-78. doi: 10.1093/clinids/22.supplement_2.s166.
4
Role of azoles in antifungal therapy.唑类药物在抗真菌治疗中的作用。
Clin Infect Dis. 1996 May;22 Suppl 2:S148-53. doi: 10.1093/clinids/22.supplement_2.s148.
5
Lipid formulations of amphotericin B: recent progress and future directions.两性霉素B的脂质制剂:近期进展与未来方向。
Clin Infect Dis. 1996 May;22 Suppl 2:S133-44. doi: 10.1093/clinids/22.supplement_2.s133.
6
Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.1980 - 1990年美国医院获得性真菌感染流行病学的长期趋势。国家医院感染监测系统。
J Infect Dis. 1993 May;167(5):1247-51. doi: 10.1093/infdis/167.5.1247.
7
In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184.新型制霉菌素衍生物BMS-181184的体外抗真菌和杀菌谱
Antimicrob Agents Chemother. 1995 Feb;39(2):295-300. doi: 10.1128/AAC.39.2.295.
8
Determination of robust ocular pharmacokinetic parameters in serum and vitreous humor of albino rabbits following systemic administration of ciprofloxacin from sparse data sets by using IT2S, a population pharmacokinetic modeling program.通过使用群体药代动力学建模程序IT2S,从稀疏数据集中确定全身给予环丙沙星后白化兔血清和玻璃体液中的稳健眼药代动力学参数。
Antimicrob Agents Chemother. 1995 Aug;39(8):1683-7. doi: 10.1128/AAC.39.8.1683.
9
Pradimicin, a novel class of potent antifungal antibiotics.普拉地米星,一类新型强效抗真菌抗生素。
J Antibiot (Tokyo). 1988 Nov;41(11):1701-4. doi: 10.7164/antibiotics.41.1701.
10
Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits.用于诱导、维持和支持兔持续性粒细胞减少症的慢性硅橡胶中心静脉置管术。
Lab Anim Sci. 1988 Aug;38(4):467-71.

普拉地米星衍生物BMS 181184在兔体内的房室药代动力学和组织药物分布

Compartmental pharmacokinetics and tissue drug distribution of the pradimicin derivative BMS 181184 in rabbits.

作者信息

Groll A H, Sein T, Petraitis V, Petraitiene R, Callender D, Gonzalez C E, Giri N, Bacher J, Piscitelli S, Walsh T J

机构信息

Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

出版信息

Antimicrob Agents Chemother. 1998 Oct;42(10):2700-5. doi: 10.1128/AAC.42.10.2700.

DOI:10.1128/AAC.42.10.2700
PMID:9756780
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC105922/
Abstract

The pharmacokinetics of the antifungal pradimicin derivative BMS 181184 in plasma of normal, catheterized rabbits were characterized after single and multiple daily intravenous administrations of dosages of 10, 25, 50, or 150 mg/kg of body weight, and drug levels in tissues were assessed after multiple dosing. Concentrations of BMS 181184 were determined by a validated high-performance liquid chromatography method, and plasma data were modeled into a two-compartment open model. Across the investigated dosage range, BMS 181184 demonstrated nonlinear, dose-dependent kinetics with enhanced clearance, reciprocal shortening of elimination half-life, and an apparently expanding volume of distribution with increasing dosage. After single-dose administration, the mean peak plasma BMS 181184 concentration (Cmax) ranged from 120 microg/ml at 10 mg/kg to 648 microg/ml at 150 mg/kg; the area under the concentration-time curve from 0 to 24 h (AUC0-24) ranged from 726 to 2,130 microg . h/ml, the volume of distribution ranged from 0.397 to 0.799 liter/kg, and the terminal half-life ranged from 4.99 to 2.31 h, respectively (P < 0.005 to P < 0.001). No drug accumulation in plasma occurred after multiple daily dosing at 10, 25, or 50 mg/kg over 15 days, although mean elimination half-lives were slightly longer. Multiple daily dosing at 150 mg/kg was associated with enhanced total clearance and a significant decrease in AUC0-24 below the values obtained at 50 mg/kg (P < 0.01) and after single-dose administration of the same dosage (P < 0.05). Assessment of tissue BMS 181184 concentrations after multiple dosing over 16 days revealed substantial uptake in the lungs, liver, and spleen and, most notably, dose-dependent accumulation of the drug within the kidneys. These findings are indicative of dose- and time-dependent elimination of BMS 181184 from plasma and renal accumulation of the compound after multiple dosing.

摘要

在正常、插有导管的兔血浆中,对抗真菌的普拉地米星衍生物BMS 181184进行单剂量及每日多次静脉注射给药,剂量分别为10、25、50或150mg/kg体重后,对其药代动力学进行了表征,并在多次给药后评估了组织中的药物水平。采用经验证的高效液相色谱法测定BMS 181184的浓度,并将血浆数据模拟为二室开放模型。在所研究的剂量范围内,BMS 181184表现出非线性、剂量依赖性动力学,清除率增加、消除半衰期倒数缩短,且随着剂量增加分布容积明显增大。单剂量给药后,血浆中BMS 181184的平均峰浓度(Cmax)在10mg/kg时为120μg/ml,在150mg/kg时为648μg/ml;0至24小时浓度-时间曲线下面积(AUC0-24)在726至2130μg·h/ml之间,分布容积在0.397至0.799升/千克之间,终末半衰期分别在4.99至2.31小时之间(P<0.005至P<0.001)。在15天内每日多次给予10、25或50mg/kg剂量后,血浆中未发生药物蓄积,尽管平均消除半衰期略长。每日多次给予150mg/kg剂量与总清除率增加以及AUC0-24显著低于50mg/kg时的值(P<0.01)以及单剂量给予相同剂量后的值(P<0.05)相关。在16天内多次给药后评估组织中BMS 181184的浓度,结果显示肺、肝和脾中有大量摄取,最显著的是药物在肾脏中的剂量依赖性蓄积。这些发现表明BMS 181184从血浆中的消除呈剂量和时间依赖性,且多次给药后该化合物在肾脏中蓄积。